Background:

Atglistatin is a potent and selective inhibitor of ATGL with IC50 value of 0.7 μM [1].

Adipose triglyceride lipase (ATGL) is a rate-limiting enzyme in the mobilization of fatty acids from cellular triglyceride stores. Deregulated fatty acid metabolism may lead to metabolic disorders and dyslipidemic [1].

Atglistatin is a potent and selective ATGL inhibitor. In lysates from E. coli overexpressing ATGL, atglistatin inhibited ATGL activity with IC50 value of 0.7 μM. Atglistatin at concentrations up to 50 μM had no cytotoxicity. Also, atglistatin inhibited ATGL with Ki value of 355 nM in a competitive way. In white adipose tissue (WAT) lysates of wild-type mice, atglistatin inhibited triacylglycerol (TG) hydrolase activity by 78%. The combination of Atglistatin and the HSL inhibitor Hi 76-007917 inhibited TG hydrolase activity by 95%. In WAT cultures of wild-type mice, atglistatin reduced FA and glycerol release up to 72% and 62% respectively in the presence of forskolin [1].

In fasted wild-type C57Bl/6J mice, atglistatin inhibited lipolysis in a dose- and time-dependent way. Atglistatin reduced plasma TG levels by 43% and decreased glycerol and FA levels up to 62% and 50% respectively in a dose dependent way [1].

Reference:
[1].  Mayer N, Schweiger M, Romauch M, et al. Development of small-molecule inhibitors targeting adipose triglyceride lipase. Nat Chem Biol, 2013, 9(12): 785-787.